GenEdit
CA - BrisbaneBiotechnology
Focus: GenEdit is a Series B biotechnology company developing nonviral CRISPR-delivery systems for gene therapy applications. The company operates at an early stage with a focused technology platform.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
Funding Stage
SERIES B
Open Jobs
3-3 this month
Stable — net -3 jobs in 30d
0 added, 3 removed. Backfill posture.
Should You Work at GenEdit?
AI assessmentBest suited for early-stage technologists willing to trade stability and mentorship depth for equity upside and hands-on platform-building experience.
Why Work Here
- Early-stage platform play in CRISPR gene therapy with a differentiated nonviral delivery approach, offering equity upside potential typical of Series B biotech
- Opportunity to build foundational infrastructure across R&D and general administration during company scaling phase
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for GenEdit
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.